2023 Portfolio Analytics Co-Op

The Role:

The Program & Portfolio Management (P&PM) Office at Moderna is responsible for management of the development portfolio from lead nomination to licensure. This role will report to either the Director of Portfolio Analytics & Governance, or the AD of Portfolio Analytics, and support the team as we build out exciting new capabilities within PA&G. The role will give a candidate exposure to a dynamic organization that is evolving to support the generation of actionable insights and data-driven decision making across the growing portfolio. The candidate will increase their knowledge of the drug development process and learn how data and analytics can be a value driver for Clinical Development. Additionally, the successful candidate will gain exposure to key cross-functional stakeholders within the Clinical Development Organization, Informatics, Finance, Strategy, and Program Management.

Key responsibilities include analytical support on capability projects (resource management, clinical trial forecasting) and helping drive the adoption of new tools for efficiently managing our resources across our growing pipeline. Specifically, the tools we are building support teams to forecast headcount demand, and highlight gaps, as well as effectively forecast and budget financial resources on programs and clinical trials as operational assumptions evolve.

Our summer/fall co-op program is from July 17-December 15, 2023. All applicants must be available for the entire duration of the program.

Heres What Youll Do:

A key project will include supporting the adoption of a new capability for budgeting and forecasting our clinical trial expenses.

• Support workstream(s) to upscale our clinical trial budgeting and forecasting capabilities across the portfolio within CDO

• Collaborate with key functions such as PA&G, Clinical Trial Excellence (CTE), Clinical Operations and Finance to improve our operating model and adoption of new tools

• Refine training and communication plans

• Support the development long range plan (LRP) process over the summer, including but not limited to modeling and analysis of resource demand tied to the portfolio in our new iPM tool

• Support adoption and continuous improvement of our resource management toolset

• Support the portfolio analytics and governance team in day to day operations

• Assist in resolving business challenges using systems and data

• Learn more about mRNA drug development, the CDO organization and Moderna

Heres What Youll Bring to the Table:

• Enrolled in a full-time Masters program, or Masters of finance graduate, with at least 1-2 years of experience working for pharmaceutical/biotech company in finance, business operations, analytics & insights, or a similar function

• Academic or professional background in a business discipline (e.g. finance, economics) or discipline related to drug discovery and development (e.g., biology, chemistry, biochemistry, molecular biology)

• Strong problem-solving skills

• Curious, independent self-starter with strong collaboration skills

• Advanced verbal and written communication skills

• Strong PowerPoint and Excel skills

• Preferred: Experience with data visualization and dashboard tools (Spotfire, Looker, Tableau, etc.)

• Preferred: Working knowledge of clinical development

Moderna is pleased to provide you with an innovative suite of benefits, including:

• Free premium access to meditation and mindfulness classes
• Free parking or subsidized commuter passes
• Generous paid time off, including:
  Vacation, sick time and holidays
  Volunteer time to participate within your community
  Discretionary year-end shutdown
• Location-specific perks and extras!

Candidates should be aware that Moderna currently maintains a policy requiring all US-based employees to be fully vaccinated against COVID-19 and receive a booster shot once eligible. Newly hired employees must be vaccinated and boosted prior to their employment start date. Moderna is an equal opportunity employer and will provide a reasonable accommodation to those unable to be vaccinated or receive a booster where it is not an undue hardship to the company to do so as provided under federal, state, and local law.

About Moderna

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.

Moderna is a smoke-free, alcohol-free and drug-free work environment.

Moderna is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a persons race, color, gender, age, religion, national origin, ancestry, disability, veteran status, genetic information, sexual orientation or any characteristic protected under applicable law. Moderna will make reasonable accommodations for qualified individuals with known disabilities, in accordance with applicable law.

-